Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 24 10 2023
accepted: 14 02 2024
revised: 07 02 2024
medline: 15 4 2024
pubmed: 28 2 2024
entrez: 27 2 2024
Statut: ppublish

Résumé

CIC::DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of patient tumor samples and cell lines. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS). Remarkably, chimeric mice from all three conditional models developed spontaneous soft tissue tumors and disseminated disease in the absence of Cre-recombinase. The penetrance of spontaneous (Cre-independent) tumor formation was complete irrespective of bi-allelic Cic function and the distance between adjacent loxP sites. Characterization of soft tissue and presumed metastatic tumors showed that they consistently expressed the CIC::DUX4 fusion protein and many downstream markers of the disease credentialing the models as CDS. In addition, tumor-derived cell lines were generated and ChIP-seq was preformed to map fusion-gene specific binding using an N-terminal HA epitope tag. These datasets, along with paired H3K27ac ChIP-sequencing maps, validate CIC::DUX4 as a neomorphic transcriptional activator. Moreover, they are consistent with a model where ETS family transcription factors are cooperative and redundant drivers of the core regulatory circuitry in CDS.

Identifiants

pubmed: 38413794
doi: 10.1038/s41388-024-02984-8
pii: 10.1038/s41388-024-02984-8
pmc: PMC11027086
mid: NIHMS1983325
doi:

Substances chimiques

Biomarkers, Tumor 0
Oncogene Proteins, Fusion 0
Proto-Oncogene Proteins c-ets 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1223-1230

Subventions

Organisme : NCI NIH HHS
ID : R38 CA245204
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197616
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : UpdateOf

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Cancer Res. 2022 Feb 15;82(4):708-720
pubmed: 34903601
Cancer Res. 2018 Oct 1;78(19):5513-5520
pubmed: 30093562
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20776-20784
pubmed: 32788348
Am J Surg Pathol. 2013 Sep;37(9):1379-86
pubmed: 23887164
Cancer Res. 2017 Jun 1;77(11):2927-2937
pubmed: 28404587
Nat Med. 2007 Aug;13(8):992-7
pubmed: 17676052
EMBO J. 2010 Jul 7;29(13):2147-60
pubmed: 20517297
Oncogene. 2004 Feb 26;23(8):1558-65
pubmed: 14661057
Oncogenesis. 2021 Oct 12;10(10):68
pubmed: 34642317
Cancers (Basel). 2022 Nov 02;14(21):
pubmed: 36358827
Am J Transl Res. 2021 Nov 15;13(11):12181-12194
pubmed: 34956445
Cancer Med. 2022 Apr;11(8):1805-1816
pubmed: 35178869
Genes Chromosomes Cancer. 2012 Mar;51(3):207-18
pubmed: 22072439
Nat Med. 2023 Mar;29(3):656-666
pubmed: 36932241
Oncotarget. 2015 Mar 10;6(7):5217-36
pubmed: 25595908
Cell Rep. 2022 Oct 4;41(1):111443
pubmed: 36198276
Nature. 2001 Apr 26;410(6832):1111-6
pubmed: 11323676
Hum Mol Genet. 2006 Jul 1;15(13):2125-37
pubmed: 16717057
Mol Cell Biol. 2000 Jan;20(2):648-55
pubmed: 10611243
Cancer Res. 2023 Dec 1;83(23):3846-3860
pubmed: 37819236
Mod Pathol. 2016 Dec;29(12):1523-1531
pubmed: 27562494
Trends Cancer. 2021 Jan;7(1):77-86
pubmed: 32978089
Nat Commun. 2020 Dec 17;11(1):6410
pubmed: 33335088
BMC Evol Biol. 2010 Nov 26;10:364
pubmed: 21110847
Nat Genet. 2017 Jun;49(6):925-934
pubmed: 28459457
Am J Surg Pathol. 2017 Mar;41(3):423-429
pubmed: 27879517
Genes Chromosomes Cancer. 2014 Jul;53(7):622-33
pubmed: 24723486
Cancer Cytopathol. 2016 May;124(5):350-61
pubmed: 26800124
Genome Res. 2016 Mar;26(3):385-96
pubmed: 26843070
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
Nature. 2018 Oct;562(7727):367-372
pubmed: 30283141
Cancer Genet Cytogenet. 2009 Nov;195(1):1-11
pubmed: 19837261
Am J Surg Pathol. 2017 Jul;41(7):941-949
pubmed: 28346326
Hum Pathol. 2012 Feb;43(2):180-9
pubmed: 21813156
J Clin Invest. 2019 Jul 22;129(8):3401-3406
pubmed: 31329165

Auteurs

Peter G Hendrickson (PG)

Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.

Kristianne M Oristian (KM)

Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.

MaKenna R Browne (MR)

Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Developmental and Stem Cell Biology Program, Duke University Medical Center, Durham, NC, USA.

Lixia Luo (L)

Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.

Yan Ma (Y)

Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.

Diana M Cardona (DM)

Department of Pathology, Duke University Medical Center, Durham, NC, USA.

Joshua O Nash (JO)

Program in Genetics and Genome Biology, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, ON, Canada.
Laboratory of Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Pedro L Ballester (PL)

Laboratory of Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Scott Davidson (S)

Laboratory of Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Adam Shlien (A)

Program in Genetics and Genome Biology, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, ON, Canada.
Laboratory of Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Corinne M Linardic (CM)

Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA.

David G Kirsch (DG)

Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA. David.kirsch@uhn.ca.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA. David.kirsch@uhn.ca.
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. David.kirsch@uhn.ca.
Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. David.kirsch@uhn.ca.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. David.kirsch@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH